Citations

Showing 10 of 108094 citations.

Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma
Furqan, Fateeha , Ahn, Kwang Woo , Abutalib, Syed A., Ahmed, Sairah , Kharfan‐Dabaja, Mohamed A. , Friedberg, Johnathan, Gregory, Tara, Hill, LaQuisa C. , Sterling, Cole , Barta, Stephan K., Herrera, Alex F. , Sauter, Craig S. , Ahmed, Sairah , Perales, Miguel-Angel , Hamadani, Mehdi , Hill, LaQuisa C , Chen, Yue , Kaur, Manmeet, Ahmed, Nausheen , Shadman, Mazyar , Perales, Miguel‐Angel , Zain, Jasmine , Hamadani, Mehdi

Mayo Clinic

British Journal of Haematology | September 19, 2022 | Volume: 200 | Issue: 1 | Pages: 54-63

10.1111/bjh.18467 | PMID 36120837 Get It

Summary The prognosis of relapsed/refractory (R/R) anaplastic large cell lymphoma (ALCL) is poor. Large studies evaluating outcomes of allogeneic haematopoietic cell transplantation (allo‐HCT) in systemic R/R ALCL are not available. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we evaluated outcomes of 182 adults (aged ≥18 years) with R/R ALCL undergoing allo‐HCT between 2008 and 2019. Non‐relapse mortality (NRM), disease relapse/progression (REL), progression‐free survival (PFS), and overall survival (OS) were modelled using Cox proportional hazards models. The median (range) follow‐up of survivors was 62 (3–148) months. The 1‐year NRM was 18%. The 5‐year REL, PFS and OS were 32%, 41% and 56% respectively. On multivariable regression analysis African American race (hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.6–4.8; p < 0.001) and refractory disease at allo‐HCT (HR 3.2, 95% CI 1.6–6.2; p < 0.001) were predictive of inferior OS. Similarly, African‐American race (HR 2.1, 95% CI 1.3–3.4; p = 0.003), other minority race (HR 2.5, 95% CI 1.2–5.3; p = 0.02) and refractory disease (HR 2.2, 95% CI 1.2–4.3; p = 0.01) were predictive of inferior PFS. These data, demonstrate that allo‐HCT can result in durable disease control in a sizable proportion of patients with R/R ALCL. Refractory disease and racial minority status predicted inferior allo‐HCT outcomes. Whether the inferior outcomes of racial minorities with R/R ALCL after allo‐HCT are driven by differences in disease biology or disparities in post allo‐HCT care, or both, requires further investigation.
Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study
Joshi, Utsav , Bhattarai, Adheesh , Gaire, Suman , Gill, Simrat, Agrawal, Vishakha , Yadav, Sumeet Kumar, Low, Soon Khai , Dhakal, Prajwal , Dhakal, Prajwal , Bhatt, Vijaya Raj , Kouides, Peter A.

Mayo Clinic

Leukemia & Lymphoma | September 19, 2022 | Volume: 63 | Issue: 14 | Pages: 3456-3461

10.1080/10428194.2022.2123227 | PMID 36120968 Get It

Prescription opioids and longitudinal changes in cognitive function in older adults: A population‐based observational study
Hanson, Andrew C. , Schulte, Phillip J. , Warner, Nafisseh S. , Habermann, Elizabeth B. , Warner, David O. , Mielke, Michelle M.

Mayo Clinic

Journal of the American Geriatrics Society | September 18, 2022 | Volume: 70 | Issue: 12 | Pages: 3526-3537

10.1111/jgs.18030 | PMID 36117241 Get It

Abstract Background Opioids are frequently prescribed to alleviate pain in older adults, yet the relationships between prescription opioids and long‐term cognitive function are unclear. Methods In this analysis of the Mayo Clinic Study of Aging, a longitudinal population‐based cohort study of older adults with formal neuropsychological testing and cognitive evaluations performed every 15 months, the associations between prescription opioids, global and domain‐specific cognitive function, and mild cognitive impairment were evaluated through time‐dependent linear mixed effects and Cox proportional hazards models. Results Four thousand two hundred eighteen participants (51% male) were included with enrollment between 11/1/2004 and 4/1/2019 and median age of 76 (interquartile range 72, 82) years. Two thousand nine hundred seventy‐seven subjects (71%) received at least 1 opioid prescription during a median follow‐up of 7.5 (5.0, 10.7) years. Overall, there was an estimated 0.096 reduction in the global cognitive Z ‐score per year, including decreases of 0.050 in memory, 0.080 in language, 0.044 in visual–spatial cognition, and 0.112 in attention. In multivariable analyses, each receipt of an opioid prescription resulted in an additional −0.007 (95% CI −0.009, −0.005) change in global cognitive Z ‐score ( p < 0.001), with significant effects seen in the domains of memory (−0.005, 95% CI −0.007, −0.003; p < 0.001), language (−0.002, 95% CI −0.003, 0.000; p = 0.024) and attention (−0.004, 95% CI −0.006, −0.002; p < 0.001) but not visual–spatial function (0.000, 95% CI −0.001, 0.001; p = 0.897). Opioid prescriptions were associated with incident mild cognitive impairment (MCI) in adjusted analysis (hazard ratio 1.21, 95% CI 1.04, 1.42; p = 0.014). Conclusion Prescription opioids are associated with small but statistically significant declines in long‐term cognitive function in older adults, which may represent effects of opioids or other related factors.
Novel Endoscopic Bariatric Therapies for the Management of Nonalcoholic Steatohepatitis
Gala, Khushboo, Razzak, Farah Abdul, Rapaka, Babusai , Gala, Khushboo , Razzak, Farah Abdul, Dayyeh, Barham K. Abu

Mayo Clinic

Seminars in Liver Disease | September 18, 2022 | Volume: 42 | Issue: 04 | Pages: 446-454

10.1055/a-1946-6285 | PMID 36116439 Get It

Obesity is strongly associated with nonalcoholic fatty liver disease as well as advanced forms of the disease such as nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. While lifestyle and diet modifications have been the cornerstone of treatment for NASH thus far, they are only effective for less than half of the patients. New endoscopic bariatric therapies (EBTs) have already proved to be safe and effective for the treatment of obesity and type 2 diabetes mellitus, and may provide an intermediate, less invasive, cost-effective option for patients with NASH. In this review, we aim to describe the data and evidence as well as outline future areas of development for endobariatric therapies for the treatment of NASH. In conclusion, EBTs present an effective and safe therapeutic modality for use in the growing pandemic of obesity-related liver disease and should be investigated further with large-scale trials in this patient population.
Effects of Elamipretide on Autophagy in Renal Cells of Pigs with Metabolic Syndrome
Hong, Siting , Ghandriz, Ramyar , Siddiqi, Sarosh , Zhu, Xiangyang , Saadiq, Ishran M. , Jordan, Kyra L., Ali, Khaled A., Eirin, Alfonso , Lerman, Lilach O. , Eirin, Alfonso , Lerman, Lilach O , Tang, Hui Jun , Ali, Khaled A., Lerman, Amir

Mayo Clinic

Cells | September 18, 2022 | Volume: 11 | Issue: 18 | Pages: 2891

10.3390/cells11182891 | PMID 36139466 Get It

Autophagy eliminates excessive nutrients and maintains homeostasis. Obesity and metabolic syndrome (MetS) dysregulate autophagy, possibly partly due to mitochondria injury and inflammation. Elamipretide (ELAM) improves mitochondrial function. We hypothesized that MetS blunts kidney autophagy, which ELAM would restore. Domestic pigs were fed a control or MetS-inducing diet for 16 weeks. During the 4 last weeks, MetS pigs received subcutaneous injections of ELAM (0.1 mg/kg/day, MetS + ELAM) or vehicle (MetS), and kidneys were then harvested to measure protein expression of autophagy mediators and apoptosis. Systemic and renal venous levels of inflammatory cytokines were measured to calculate renal release. The function of isolated mitochondria was assessed by oxidative stress, energy production, and pro-apoptotic activity. MetS slightly downregulated renal expression of autophagy mediators including p62, ATG5-12, mTOR, and AMPK vs. control. Increased mitochondrial H2O2 production accompanied decreased ATP production, elevated apoptosis, and renal fibrosis. In MetS + ELAM, mito-protection restored autophagic protein expression, improved mitochondrial energetics, and blunted renal cytokine release and fibrosis. In vitro, mitoprotection restored mitochondrial membrane potential and reduced oxidative stress in injured proximal tubular epithelial cells. Our study suggests that swine MetS mildly affects renal autophagy, possibly secondary to mitochondrial damage, and may contribute to kidney structural damage in MetS.
Tumor Microenvironment CD14+ Cells Correlate with Poor Overall Survival in Patients with Early-Stage Lung Adenocarcinoma
Withers, Sarah G., Bulur, Peggy A. , Dietz, Allan B. , Boland, Jennifer M. , Dietz, Allan B , Schenk, Erin L.

Mayo Clinic

Cancers | September 18, 2022 | Volume: 14 | Issue: 18 | Pages: 4501

10.3390/cancers14184501 | PMID 36139660 Get It

Patients with early-stage lung adenocarcinoma have a high risk of recurrent or metastatic disease despite undergoing curative intent therapy. We hypothesized that increased CD14+ cells within the tumor microenvironment (TME) could stratify patient outcomes. Immunohistochemistry for CD14 was performed on 189 specimens from patients with lung adenocarcinoma who underwent curative intent surgery. Outcomes and associations with clinical and pathologic variables were determined. In vitro studies utilized a coculture system to model the lung cancer TME containing CD14+ cells. Patients with high levels of TME CD14+ cells experienced a median overall survival of 5.5 years compared with 8.3 and 10.7 years for those with moderate or low CD14 levels, respectively (p < 0.001). Increased CD14+ cell tumor infiltration was associated with a higher stage at diagnosis and more positive lymph nodes at the time of surgery. This prognostic capacity remained even for patients with early-stage disease. Using an in vitro model system, we found that CD14+ cells reduced chemotherapy-induced cancer cell death. These data suggest that CD14+ cells are a biomarker for poor prognosis in early-stage lung adenocarcinoma and may promote tumor survival. CD14+ cell integration into the lung cancer TME can occur early in the disease and may be a promising new therapeutic avenue.
Management of Diverticulitis in Renal Transplant Patients
Batra, Rishi , Rudnicki, Yaron , Stapleton, Sahael M. , Gan, Tong, Mathis, Kellie L. , Gan, Tong J. , Stapleton, Sahael, Kelley, Scott R.

Mayo Clinic

The American Surgeon™ | September 18, 2022 | Volume: 89 | Issue: 2 | Pages: 210-215

10.1177/00031348221126970 | PMID 36120834 Get It

Background Renal transplant patients presenting with diverticulitis remain a clinical challenge for health care professionals. Secondary to immunosuppression, renal transplant recipients are often considered for early operative intervention due to concerns for an unreliable physical exam and feared morbidity and mortality associated with non-operative management. Methods This study aimed to evaluate trends in management of renal transplant patients with diverticulitis at a quaternary referral center. Results One hundred ninety-one renal transplant patients admitted to the hospital with diverticulitis were identified. Of this cohort, 71 (37%) underwent surgical resection, of which 20 (28%) were performed emergently. The overall 30-day operative mortality was 8% (6/71), of which there was a significant difference between emergent (25%, 5/20) and elective (2%, 1/51) groups ( P = .006). Patients who underwent elective surgery were more likely to receive a minimally invasive approach (51%) and were significantly more likely to undergo stoma reversal ( P = .006). Discussion Our study shows that not all renal transplants with diverticulitis will require operative intervention and many can be safely treated non-operatively. Elective resection and surgical management should be considered on an individual basis. Patients treated with elective resection were more likely to undergo a minimally invasive approach and restoration of intestinal continuity.
It’s time to change how we talk about alcohol
Farkouh, Elizabeth K. , Zapotocky, P , Giesbrecht, Norman , Farkouh, E K , Zapotocky, P , Giesbrecht, N

Mayo Clinic

Perspectives in Public Health | September 17, 2022 | Volume: 142 | Issue: 5 | Pages: 255-256

10.1177/17579139221093163 | PMID 36120919 Get It

A retrospective case series of prophylactic neurectomy during total knee arthroplasty
Guier, Christian G, Shi, Glenn G. , Clendenen, Steven R. , Chase, Lori A. , Wilke, Benjamin K. , Wilke, B K , Clendenen, Steven R , Shi, Glenn G , Heckman, Michael G.

Mayo Clinic

Journal of Orthopaedic Surgery | September 17, 2022 | Volume: 30 | Issue: 3 | Pages: No page available

10.1177/10225536221127460 | PMID 36120741 Get It

Introduction Total knee arthroplasty is a common operation performed to relieve pain and restore functional activity. While overall widely successful, a subset of patients has continued pain postoperatively with no identifiable cause. Neuroma formation has been identified as a possible contributor to this unexplained pain, often necessitating an additional procedure for neuroma removal. The purpose of our study was to evaluate if prophylactic neurectomy could reduce the occurrence of postoperative pain. Methods A total of 112 patients were compared, 44 control patients and 68 neurectomy patients. Demographic information, Numerical rating pain scale (NRS) and Knee Society Scores (KSS) were collected pre- and post-operatively. Patients were additional asked if they were overall satisfied with the operation. Results There were no differences between groups with respect to age (Median: 71 vs 69 years, p = 0.28), male sex (41% vs 44%, p = 0.85), or body mass index (Median: 32.2 vs 31.3, p = 0.80). When comparing the degree of change following surgery there were no statistically significant differences observed in NRS pain scores (Median change: −7 vs −6, p = 0.89) or KSS scores (Median change: +44 vs +40, p = 0.14). Similarly, there was no statistically significant difference in overall patient-reported satisfaction with the knee replacement (82.5% vs 86.6%, p = 0.59). Conclusion We did not find a statistically significant difference in NRS, KSS, or overall patient satisfaction between the prophylactic neurectomy and control patient groups. Larger studies with evaluation of the nerve diameter will be needed to determine which patients are at risk for symptomatic neuroma development following total knee arthroplasty.
Parents’ perspective on COVID-19 vaccine in children 6 months through 4 years: a cross-sectional study from Northwest Wisconsin
Mangat, Chetna , Rich, Jennifer, Sanghavi, Devang , Schmidt, Rebecca , Milosavljevic, Natasa, Linh, Tran , Bansal, Pankaj , Bansal, Pankaj , Rich, Jennifer, Schmidt, Rebecca

Mayo Clinic

BMJ Open | September 17, 2022 | Volume: 12 | Issue: 9 | Pages: e065453

10.1136/bmjopen-2022-065453 | PMID 36115680 Get It

Vaccination is critical to control the ongoing COVID-19 pandemic, but despite the availability of safe and effective vaccine in children over 5 years, vaccination rates remain low. There is paucity of data about vaccine acceptance and factors influencing parents’ hesitancy about the COVID-19 vaccine for young children. Aims and objectives To estimate vaccine acceptance by parents of children 6 months through 4 years, and to evaluate the factors influencing vaccine hesitancy. Methods Electronic survey was sent to parents of children 6 months through 4 years through an online portal account at Mayo Clinic Health System, Northwest-Wisconsin. Data were captured via Research Electronic Data Capture secured data collection software. Bivariate and multivariate regression was used to determine most pertinent factors influencing parents’ decisions against the outcome, ‘Intent to Vaccinate’. Results 39.7% of the parents were ‘very likely’ or ‘somewhat likely ’ to vaccinate their children once the vaccine became available, while 49.8% were not likely or highly unlikely to vaccinate. Routine childhood vaccination, receiving seasonal influenza vaccine, parents' perception of COVID-19 severity in children and safety and effectiveness of the vaccine were all associated with more vaccine acceptance. 71.4% of parents who will likely not vaccinate their children indicated that they are unlikely to change their decision. The need for more research on the vaccine and more information from the PCP office were the most common reasons behind the vaccine decision-making. Conclusions Vaccine hesitancy remains a major issue regarding uptake of the upcoming COVID-19 vaccine. Strong and clear evidence-based recommendations from primary care provider and more information from trusted websites such as Centers for Disease Control and Prevention can decrease vaccine hesitancy in parents. Further research targeted at understanding beliefs and perspectives of parents from different demographics can assist policy-makers in implementing measures to improve vaccination rates in children and tailor our dialogue to match the needs of our patients and families.